Sanofi-Aventis has won FDA priority review for a new indication for its blockbuster blood thinner Lovenox.The FDA will review Lovenox for treatment of patients suffering acute ST-segment elevation ...

Unlike unfractionated heparin (UFH), the low-molecular-weight heparin enoxaparin (Lovenox) is excreted mainly by the kidneys. To determine whether this characteristic heightens bleeding risk in ...

Rockville, MD - The FDA's MedWatch program and Aventis Pharmaceuticals have issued a reminder to physicians about the use of enoxaparin (Lovenox TM) in patients with renal impairment. According to ...

(Reuters) - The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding ...

NEW YORK, Dec 10 (Reuters) - Johnson & Johnson said on Monday that a pill it is developing with Bayer AG was far better able to prevent blood clots among patients after knee and hip replacements than ...

Well, we sort of figured this was coming. Sanofi-Aventis has gone to court here in Washington to prevent rival drugmaker Novartis from selling a generic version of the blockbuster blood-thinner ...

BRIDGEWATER, N.J., Feb. 7 (UPI) -- Sanofi-aventis said Wednesday the U.S. Food and Drug Administration granted its blood-thinner Lovenox priority review for acute heart attack. The company said it is ...

Johnson & Johnson said today a pill it is developing with Bayer was far better able to prevent blood clots among patients after knee and hip replacements than Sanofi-Aventis'injectable Lovenox, the ...